Determining vancomycin clearance in an overweight and obese population

Area of Science:

• Pharmacokinetics and Pharmacodynamics
• Clinical Pharmacology
• Nephrology

Background:

• Accurate vancomycin dosing is critical for efficacy and safety, especially in overweight and obese patients.
• Traditional weight-based dosing may be suboptimal in this population.
• Understanding optimal weight metrics for vancomycin clearance is essential.

Purpose of the Study:

• To compare two methods for calculating vancomycin clearance.
• To determine the best body weight measure for vancomycin dosing in overweight and obese patients.
• To evaluate the precision and bias of different dosing methods.

Main Methods:

• Retrospective study of hospitalized veterans (BMI > 120% ideal body weight).
• Compared Leonard and Boro method with Rushing and Ambrose method.
• Utilized serum vancomycin concentrations (SVCs) and adjusted body weight (ABW).

Main Results:

• Adjusted body weight (ABW) was superior to total body weight in predicting vancomycin clearance and SVCs in phase 1.
• The modified Leonard and Boro method demonstrated significantly greater precision than the Rushing and Ambrose method in phase 2.
• No significant difference in bias was observed between the methods.

Conclusions:

• Adjusted body weight (ABW) is the preferred weight measure for estimating vancomycin clearance in overweight and obese patients.
• The modified Leonard and Boro method provides more precise predictions of SVCs for vancomycin dosing in obese individuals.
• Optimizing vancomycin dosing in obese patients requires careful consideration of weight metrics and calculation methods.